Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1127500

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256255
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256254 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1126022

registered interest
date	13/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will expedite the process by which the NICE publishes its decisions.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	253483
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The Government wants patients to be able to benefit from access to effective new treatments as quickly as possible.</p><p>Through its technology appraisal and highly specialised technologies guidance, the National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations on whether medicines and other treatments represent a clinically and cost effective use of National Health Service resources. NHS organisations are legally required to make funding available for NICE recommended treatments, usually within three months of final guidance.</p><p>Wherever possible, NICE currently aims to publish recommendations on new drugs as soon as possible after licensing, with draft guidance on cancer drugs published in advance of licensing. The 2019 Voluntary Scheme for Branded Medicines Pricing and Access includes a commitment to faster NICE assessments of new medicines, with timelines for non-cancer drugs to match those for cancer drugs, subject to the evidence base for the product being sufficiently developed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/05/2019 10:58:38 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1124902

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March.
tabling member printed	Baroness Thomas of Winchester
uin	HL15577
answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15576 question first answered 17/05/2019 11:07:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3785 label Biography information for Baroness Thomas of Winchester

692195

registered interest
date	20/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what discussions they have had with NICE concerning the implementation of an abbreviated highly-specialised technologies process.
tabling member printed	Baroness Wheeler
uin	HL5489
answer	answer is ministerial correction date of answer 28/02/2017 answer text <p>The Government has had no such discussions. There are no plans for the National Institute for Health and Care Excellence to introduce an abbreviated highly specialised technologies evaluation process.</p> answering member printed Lord O'Shaughnessy question first answered 28/02/2017 15:36:12 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4157 label Biography information for Baroness Wheeler

422284

registered interest
date	19/10/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, which organisation provides the secretariat for the NICE Implementation Collaborative; what the Collaborative's current priorities and work programmes are; what funding the Collaborative has received from the public purse since it was established; and if he will make a statement.
tabling member constituency	Bromley and Chislehurst
tabling member printed	Robert Neill
uin	12412
answer	answer is ministerial correction date of answer 27/10/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that it has provided the secretariat function for the NICE Implementation Collaborative (NIC) since January 2014 as part of a wider memorandum of understanding with NHS England. This year, the NIC agreed to undertake work in the following four areas, each of which was agreed because of their potential to generate learning about how to support uptake of NICE guidance:</p><br /><p>- Improving patient outcomes for patients with non ST Elevation acute Coronary Syndromes;</p><p>- Improving Tuberculosis screening and data collection across health and social care;</p><p>- Identifying appropriate treatment pathways for people with moderate alcohol consumption across health and social care; and</p><p>- Increasing the knowledge base about the factors that increase use of technologies building on previous National Institute for Health Research (NIHR) research.</p><br /><p>NHS England has responsibility for funding any project costs and projects liaise with NHS England to access these funds.</p><br /><p>NHS England has advised that it provided £4,000 in 2014-15 and up to £10,000 in 2015-16.</p><br /> <br /> <br /><p><strong></strong></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2015 16:13:36 answering member 4020 label Biography information for George Freeman
tabling member	1601 label Biography information for Sir Robert Neill

390100

registered interest
date	15/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether it is possible to amend the National Institute for Health and Care Excellence's process and methodology for technology appraisals midway through an appraisal.
tabling member printed	Lord Mancroft
uin	HL1512
answer	answer is ministerial correction date of answer 23/07/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that it follows the processes and methodology set out in its published guidance development manuals. NICE’s processes are sufficiently flexible to enable it to respond to unique situations that arise within an appraisal. There have been occasions where changes to the published processes have been introduced during an ongoing appraisal. In such cases, full consultation with stakeholders on substantive changes have taken place before their implementation.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 23/07/2015 10:52:47 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1833 label Biography information for Lord Mancroft

227334

registered interest
date	13/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the extent to which the National Institute for Health and Care Excellence is promoting innovation in the provision of health and social care as required by the Health and Social Care Act 2012.
tabling member printed	Lord Hunt of Kings Heath
uin	HL5721
answer	answer is ministerial correction date of answer 23/03/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) plays an important role in promoting innovation in the health and care system through the development of authoritative, evidence-based guidance on the most effective and cost-effective ways to prevent and treat ill health, and through the dissemination of information on innovative new technologies. For example, in the development of its technology appraisal guidance and Highly Specialised Technologies guidance, NICE ensures that the benefits to patients from an innovative technology are fully captured in its decision-making. NICE also disseminates information on innovative new drugs and other technologies through tailored briefings for the health and care system.</p><p> </p> answering member printed Earl Howe question first answered 23/03/2015 13:55:28 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

226303

registered interest
date	10/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 2 March 2015 to Question 224947, for what reasons the data requested is aggregated over the three years 2012-14; and if he will provide the figures for (a) 2012, (b) 2013 and (c) 2014 separately.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	226914
answer	answer is ministerial correction date of answer 17/03/2015 answer text <p>I regret that the information in my answer of 2 March 2015 was not provided in the format requested. I apologise for this oversight.</p><p> </p><p> </p><p> </p><p>The information is shown in the table<sup>1</sup>.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2014</p></td></tr><tr><td><p>Patient organisations</p></td><td><p>46</p></td><td><p>39</p></td><td><p>40</p></td></tr><tr><td><p>Manufacturers</p></td><td><p>18</p></td><td><p>22</p></td><td><p>32</p></td></tr><tr><td><p>Professional organisations</p></td><td><p>58</p></td><td><p>47</p></td><td><p>49</p></td></tr><tr><td><p>Other organisations</p></td><td><p>23</p></td><td><p>12</p></td><td><p>13</p></td></tr></tbody></table><p> </p><p><sup>1</sup> Some organisations will be involved in more than one year.</p><p> </p><p> </p><p> </p><p><em>Source:</em> National Institute for Health and Care Excellence</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/03/2015 17:30:50 answering member 4020 label Biography information for George Freeman
tabling member	204 label Biography information for Paul Burstow

222971

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many statutory consultees to each technology appraisal conducted by the National Institute for Health and Care Excellence in each of the last three years were (a) patient organisations, (b) manufacturers, (c) professional organisations and (d) other organisations.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	224947
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>The National Institute for Health and Care Excellence has advised that the consultees for all technology appraisals over the years 2012-14 can be broken down into the specified groups as follows:</p><p> </p><p> </p><p> </p><p>patient organisations: 83 separate patient groups</p><p> </p><p>manufacturers: 52 separate companies</p><p> </p><p>professional organisations: 93 separate professional groups</p><p> </p><p>other organisations: 42 separate other organisations</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 02/03/2015 17:47:49 answering member 4020 label Biography information for George Freeman
tabling member	204 label Biography information for Paul Burstow

223003

registered interest
date	23/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many attendees at each National Institute for Health and Care Excellence appraisal committee meeting convened in each of the last three years were (a) industry representatives, (b) doctors, (c) other health professionals, (d) health economists, (e) researchers, (f) patient representatives, (g) lay representatives and (h) other.
tabling member constituency	Sutton and Cheam
tabling member printed	Paul Burstow
uin	224948
answer	answer is ministerial correction date of answer 02/03/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that it does not classify information about appraisal committee attendees in the format requested.</p><p> </p><p> </p><p> </p><p>Based on NICE’s assessment of attendees’ job titles, the breakdown of attendees across its four committees responsible for developing technology appraisals for the years 2012-14 was as follows:</p><p> </p><p> </p><p> </p><p>industry representatives 6</p><p> </p><p>doctors (general practitioners) 13</p><p> </p><p>other health professionals 76</p><p> </p><p>health economists 29</p><p> </p><p>researchers 0</p><p> </p><p>patient representatives 0</p><p> </p><p>lay representatives 15</p><p> </p><p>other 11</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 02/03/2015 17:49:01 answering member 4020 label Biography information for George Freeman
tabling member	204 label Biography information for Paul Burstow